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ABSTRACT
Objective To evaluate the long-term safety (up to
3 years) of treatment with pegloticase in patients with
refractory chronic gout.
Methods This open-label extension (OLE) study was
conducted at 46 sites in the USA, Canada and Mexico.
Patients completing either of two replicate randomised
placebo-controlled 6-month trials received pegloticase
8 mg every 2 weeks (biweekly) or every 4 weeks
(monthly). Safety was evaluated as the primary outcome,
with special interest in gout ﬂares and infusion-related
reactions (IRs). Secondary outcomes included urate-
lowering and clinical efﬁcacy.
Results Patients (n=149) received a mean±SD of 28
±18 pegloticase infusions and were followed for a mean
of 25±11 months. Gout ﬂares and IRs were the most
frequently reported adverse events; these were least
common in patients with a sustained urate-lowering
response to treatment and those receiving biweekly
treatment. In 10 of the 11 patients with a serious IR, the
event occurred when uric acid exceeded 6 mg/dl. Plasma
and serum uric acid levels remained <6 mg/dl in most
randomised controlled trial (RCT)-deﬁned pegloticase
responders throughout the OLE study and were
accompanied by sustained and progressive improvements
in tophus resolution and ﬂare incidence.
Conclusions The safety proﬁle of long-term pegloticase
treatment was consistent with that observed during
6 months of RCT treatment; no new safety signals were
identiﬁed. Improvements in clinical status, in the form of
ﬂare and tophus reduction initiated during RCT
pegloticase treatment in patients maintaining goal range
urate-lowering responses were sustained or advanced
during up to 2.5 years of additional treatment.
INTRODUCTION
Urate-lowering therapy is the mainstay of chronic
gout management and aims at achieving and main-
taining sub-saturating serum uric acid (SUA) concen-
trations, most often recommended as ≤0.36 mmol/l
(≤6 mg/dl).1 2 Long-term maintenance of goal range
SUA is associated with depletion of urate crystals in
synovial ﬂuid3 4 and reductions in tophus size and
ﬂare frequency.5–7 Because the rates of achieving
these improvements are related to the degree of
urate-lowering,4 6 8 the optimal therapeutic target
may be substantially lower than 6 mg/dl in patients
with severe manifestations of chronic gout,5 prompt-
ing one recommendation for a target SUA of
<5 mg/dl.9
Up to 3% of the estimated eight million patients
with gout in the USA10 fail urate-lowering manage-
ment with standard-of-care therapies (oral xanthine
oxidase inhibitors) because of drug intolerance/
contraindication or treatment refractoriness.11–13
Such patients are at risk of progression to increasing
ﬂare recurrences, gouty arthropathy, destructive
and deforming tophi and chronic pain, frequently
accompanied by impaired physical function and
poor health-related quality of life. Until recently
these patients had few or no effective urate-
lowering options to prevent or reverse gout progres-
sion. Pegloticase, a mammalian recombinant uricase
conjugated to monomethoxypoly(ethylene glycol)
(mPEG), was developed as an enzymatic alternative
for the treatment of patients with gout refractory
to conventional oral therapies and was approved in
the USA in 2010.14–16 When administered intraven-
ously, pegloticase reduces the urate concentration in
the intravascular space to below the limit of solubil-
ity (6.8 mg/dl). The resulting reduction in extracel-
lular soluble urate concentration is hypothesised to
favour dissolution of deposited urate crystals,
resulting in progressive normalisation of body urate
pools and improvements in clinical signs and symp-
toms of gout.17 18
The tolerability and efﬁcacy of pegloticase treat-
ment in patients with refractory chronic gout were
demonstrated in replicate 6-month randomised
double-blind placebo-controlled trials (RCTs).17
Pegloticase administered every 2 weeks (biweekly)
or every 4 weeks (monthly) produced treatment
responses (plasma uric acid (PUA)<6 mg/dl for
≥80% of the time during months 3 and 6) in 42%
and 35% of patients, respectively, compared with
0% for patients receiving placebo. PUA normalised
within 24 h of the ﬁrst pegloticase infusion in all
patients, but in non-responders the urate-lowering
response was lost over time. Infusion-related reac-
tions (IRs) were the most common reason for dis-
continuations in the RCTs (10% of biweekly
treated patients and 13% of monthly treated
patients).17 This report focuses on the long-term
open-label extension (OLE) of the RCTs which
provided an additional 2.5 years of safety data.
METHODS
Study design and patients
The OLE (NCT01356498) enrolled patients at 46
centres in the USA, Canada and Mexico who had
completed either of the two RCTs (NCT01356498,
NCT00325195).17 The OLE was conducted from
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December 2006 to July 2009; compliance and permission infor-
mation is provided in the online supplementary material.
Protocol amendments extended the OLE from 12 months to a
maximum of 30 months. Figure 1 summarises the OLE study
design, inclusion criteria (exclusion criteria are presented in the
online supplementary material), end points and evaluations.
Delays in treatment between the randomised trials and the
OLE resulted from administrative requirements, such as time
for Institutional Review Board approvals and site implementa-
tion. Except where speciﬁcally indicated, patients were cate-
gorised for analysis purposes according to the ﬁrst dosing
regimen administered during the OLE study.
Details of safety evaluations and prophylaxis regimens for
IRs and ﬂares are provided in the online supplementary mater-
ial. As IRs were one of the events of interest, physical examina-
tions and monitoring of vital signs were performed at the time
of all IRs and medical intervention was provided as appropriate.
For IRs occurring during infusions, the infusion could be dis-
continued, slowed by half, or interrupted and later restarted at
a slower rate.
Immunogenicity was assessed from serum collected every
12 weeks using a validated ELISA to detect IgG and IgM peglo-
ticase antibody. Antibody titres were categorised as low (≤1 :
2430) or high (>1 : 2430), consistent with the RCTs.17 Tophus
complete response was deﬁned as 100% reduction in the mea-
sured area of at least one tophus of baseline diameter ≥5 mm
without growth of any other baseline tophus or appearance of
any new tophus.
Statistical analysis
Safety and efﬁcacy end points were evaluated using descriptive
statistics in the intent-to-treat population, which included all
patients who received at least one dose of pegloticase during
the OLE study and had follow-up data. Demographic and base-
line clinical values are described in the online supplementary
material.
RESULTS
Patient disposition
A total of 225 patients were enrolled in the two RCTs and 212
patients were included in the primary efﬁcacy analysis. Of
these, 157 patients (74%) completed the RCTs and 151 (96% of
completers) entered the OLE study, including 57 (97%) patients
from the biweekly pegloticase group, 55 (93%) from the
monthly pegloticase group and all 39 patients from the placebo
group (ﬁgure 2). All patients received pegloticase in the OLE
study, except for two patients who chose observation only
after receiving monthly pegloticase in the RCTs. For patients
treated with pegloticase in the RCTs, a higher proportion of
those deﬁned as responders than those deﬁned as non-
responders completed the OLE study, as did a higher proportion
of patients allocated to placebo in the RCTs who then received
biweekly pegloticase compared with those who received
monthly pegloticase (ﬁgure 2). The most common reasons for
discontinuing treatment during the OLE study were adverse
events (AEs) in 18% (27/149) of patients and loss of urate-
lowering response in 9% (13/149).
Patients
The OLE study population had a mean age of 56.8 years (range
30–89) and 79% were men. Most patients were white (69%),
African-American (13%) or Hispanic/Latino (11%). Risk factors
were common; the most common were cardiovascular (94% of
patients had at least one cardiovascular risk factor, most com-
monly hypertension, 72%), obesity (body mass index (BMI)
≥30 kg/m2, 65%) and dyslipidaemia (52%). Chronic kidney
disease (creatinine clearance <1.0 ml/s) was present in 26% of
patients. Less commonly occurring risk factors and concomitant
medications are described in the online supplementary material.
Exposure to pegloticase
Patients received a mean of 28 pegloticase infusions (median 26;
range 1–59) during the OLE study, with RCTresponders receiving
more infusions than non-responders (mean 35 vs 26). When
exposure to pegloticase was pooled from the RCT and OLE
studies, patients received a mean of 35 infusions (range 1–70).
Thirty of 67 patients (45%) who started on monthly pegloticase
switched to biweekly treatment at some point during the OLE
study; only 12% (10/82) switched from biweekly to monthly
treatment. Overall, patients remained in the OLE study for a
mean of 25 months (median 29 months; range 0−37 months,
including a mandated end-of-study observation period (no treat-
ment) for a maximum of 6 months).
Safety
Adverse events (AEs)
Nearly all patients (98%) had at least one AE during the OLE
study (table 1). The overall incidence of AEs did not differ
between responders and non-responders from the RCTs or for
patients initially on placebo who started pegloticase biweekly
Figure 1 Study design schematic for the open-label extension study. AE, adverse event; IR, infusion-related reaction; OLE, open-label extension;
PUA, plasma uric acid; RCT, randomised controlled trial; SUA, serum uric acid.
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versus monthly. Both gout ﬂares and IRs occurred at a lower
rate with the biweekly regimen during the OLE study (2.7 per
patient per year vs 4.7 with the monthly regimen and 1.3 per
patient per year vs 2.1, respectively).
The incidence of gout ﬂares during the OLE study was
lowest for responders who had received biweekly pegloticase in
the RCTs and highest for RCT non-responders to monthly
pegloticase and patients treated with placebo in the RCTs. The
incidence of IRs in the OLE study was lowest for RCT respon-
ders regardless of pegloticase schedule and highest for RCT
non-responders to monthly pegloticase and RCT placebo
patients starting monthly pegloticase. Eleven patients (7%) dis-
continued pegloticase due to AEs, including seven patients
with IRs; six of these seven patients were RCT pegloticase
non-responders or RCT placebo-treated patients. Among all
patients with AEs judged as treatment-related by the investiga-
tors (66%, 99/149), only gout ﬂares and IRs were reported in
>5% of patients.
Most AEs (53% of patients) were investigator-rated as moder-
ate in intensity. Overall, 36% (54/149) of patients had severe
AEs, of which 17% were treatment-related, most commonly
IRs (7%) or gout ﬂares (7%). Of note, no RCT pegloticase
responder had a severe treatment-related IR or a severe gout
ﬂare. The highest rates of severe IRs and ﬂares (26% for both;
6/23) were reported in patients treated with biweekly pegloti-
case during the OLE study who had received placebo in the
RCTs. Assessments of haematology, clinical chemistry and
urinalysis identiﬁed no signiﬁcant change from baseline (except
for UA) in any of the subgroups deﬁned by response to pegloti-
case or pegloticase administration schedule.
Twenty-four adjudicated cardiovascular events in 21 patients
were identiﬁed in the OLE study by the independent expert
committee. These events occurred in responders and non-
responders with no apparent relationship to the duration of
treatment or time since the last pegloticase infusion. Eight of
these events occurred in patients who were being observed and
had not received pegloticase for >30 days.
Serious AEs and deaths
Approximately one-third of patients (34%, 51/149) experienced
a total of 106 serious AEs during the OLE study. Thirteen
patients who reported serious AEs discontinued treatment.
Among the 13 serious AEs considered possibly related to study
drug, there were 11 IRs (one serious AE of IR was judged
unlikely to be related to the study drug), one skin necrosis
(severe) and one nephrolithiasis (moderate). Among the 11
serious AEs of IR, all but one occurred when the UA values
Figure 2 Disposition for all patients entering the open-label extension (OLE) study. ITT, intention-to-treat; RCT, randomised controlled trial.
Table 1 Summary of AEs during the OLE study
All treated patients
(N=149)
AEs in the OLE study N (%)
Subjects with any AE 146 (98)
Subjects with any serious AE 51 (34)
Subjects with serious AEs considered related to
pegloticase
13 (9)
Discontinuations due to AE 11 (7)
Most common AEs (incidence >10%)
Gout flare 106 (71)
Infusion-related reaction 65 (44)
Arthralgia 29 (20)
Upper respiratory tract infection 27 (18)
Pain in extremity 26 (17)
Back pain 25 (17)
Diarrhoea 22 (15)
Peripheral oedema 21 (14)
Urinary tract infection 20 (13)
Nausea 17 (11)
Headache 16 (11)
Fatigue 15 (10)
Sinusitis 15 (10)
Nasopharyngitis 15 (10)
AE, adverse event; OLE, open-label extension.
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exceeded 6 mg/dl. Four deaths occurred during the OLE study,
all of which were judged as unlikely to be related to the study
drug by the investigator (see online supplementary material).
IRs
During the RCTs, IRs were the second most common AE and
were reported in 26% of patients receiving biweekly pegloticase
and 42% of patients receiving monthly pegloticase. In the OLE,
IRs were reported in 44% (60/149) of patients. The rate of IRs
was lower in RCT responders (17%, 10/60) than in non-
responders (52%, 26/50) and highest among patients who
received placebo in the RCT (62%, 24/39). IRs were rated mild
in 27% (16/60) of patients, moderate in 55% (33/60) and severe
in 18% (11/60). IRs rated as severe in the OLE occurred in four
patients, none of whom sustained goal range urate lowering,
and in seven patients who received placebo in the RCT. IRs
were the reason cited for withdrawal from the study for 6% (9/
149) of patients.
Except for three patients with IRs manifesting in the 2 h
period after infusion, all IRs occurred during infusion. The
most common signs and symptoms associated with IRs were
musculoskeletal pain/discomfort, ﬂushing, erythema, nausea/
vomiting, dyspnoea, sweating, headache, blood pressure
changes, urticaria and pruritus. All IRs resolved with support-
ive measures and no patient required intubation, mechanical
ventilatory support, pressors or hospitalisation. Three patients
were found to have anaphylaxis based on a retrospective
analysis. Symptoms included red, itching or swollen eyes,
throat irritation, musculoskeletal symptoms, skin ﬂushing,
hypotension, dizziness and vomiting.
Immunogenicity
A total of 31% (52/169) of patients treated with pegloticase
had high pegloticase antibody titres (>1 : 2430) during the
RCTs. High-titre antibodies were identiﬁed in 53% (67/127) of
patients at the week 13 assessment of the OLE; this number
increased by the end of the study (antibody titres >1 : 2430 in
60%; 90/149). Only one patient had evidence of in vitro neutra-
lising antibodies against uricase activity; this was measurable
at only one time point. Consistent with ﬁndings from the
RCTs,17 low titres (≤1 : 2430) of anti-pegloticase antibodies
were less likely to be associated with loss of SUA response (see
online supplementary material for supporting data).
Efﬁcacy
Serum uric acid response
The concordance of PUA and SUA (collected for all patients at
the same time points) for values above and below the target of
6 mg/dl was 95% in samples collected during the OLE study.
The efﬁcacy data reported here focus on SUA because of its
ready accessibility in clinical settings. The overall mean±SD
SUA at baseline was 10.1±1.4 mg/dl. Most responders to
biweekly and monthly pegloticase in the RCTs maintained
SUA<6 mg/dl throughout the OLE study (ﬁgure 3A). Among
Figure 3 Percentage of patients with serum uric acid (SUA) <6 mg/dl by study week, uric acid responder status in the randomised controlled trial
(RCT) and pegloticase dose regimen. (A) All patients who entered the open-label extension (OLE) study after receiving pegloticase during the RCTs.
Subgroups were deﬁned by SUA response during the RCTs. (B) All patients who entered the OLE study after receiving placebo during the RCT and
therefore had their ﬁrst exposure to pegloticase in the OLE study. Subgroups are deﬁned by the pegloticase dose administered at OLE entry.
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patients randomised to placebo in the RCTs, biweekly pegloti-
case administration in the OLE study produced greater reduc-
tions in mean SUA and a greater proportion of patients
maintaining SUA<6 mg/dl than monthly pegloticase
(ﬁgure 3B).
Tophus response
Tophus burden continued to decrease during ongoing pegloti-
case therapy. At the end of the RCTs, a complete response in at
least one tophus was reported for 40% (21/52) of patients with
tophi treated with biweekly pegloticase, 21% (11/52) of those
treated with monthly pegloticase and 7% (2/27) of those
treated with placebo. By OLE week 13 a complete response in
at least one tophus was reported for 45% (36/80) of patients
with tophi at RCT inception. At the ﬁnal OLE visit (week
125), 60% (56/94) of patients with evaluable tophi had a com-
plete response. Patients with a sustained urate-lowering
response to treatment were more likely to experience complete
tophus resolution. A complete response was seen in 87% (32/
37) of patients in the responder group and in 31% (11/36)
designated non-responders on the basis of SUA measurements
in the RCTs.
As prespeciﬁed in the protocol, each patient could have up to
ﬁve measurable (and two additional) target or index tophi.
Responses based on the total number of tophi were assessed to
complement information on the proportion of patients with
tophus complete response. After 1 year of pegloticase treatment
in the OLE study, 61% (185/302) of all target tophi had com-
pletely resolved. Among patients who qualiﬁed as responders in
the RCTs, a complete response of 70% (102/145) of all target
tophi was achieved after 1 year of open-label treatment.
Gout ﬂares
Gout ﬂares occurred in 71% of patients (106/149) during the
OLE study; the mean number of ﬂares per patient per 3-month
period was 0.5 over the duration of the trial. The highest ﬂare
rates occurred in 52% of patients (78/149; 1.1 ﬂares/patient)
during the ﬁrst 3-month period. Flare rates diminished with
continued treatment in the OLE among patients who were
urate-lowering responders during the RCT compared with
patients who were RCT non-responders (ﬁgure 4A,B). For
example, in the cohort of patients sustaining goal urate-
lowering on the biweekly pegloticase OLE dose schedule, ﬂares
diminished substantially (occurring in 26% (9/35) during
months 1–3 of the OLE study, 9% (3/32) during months 10–12
and 3% (1/29) during months 22–24).
DISCUSSION
Pegloticase is a PEGylated mammalian recombinant uricase
that was developed to control hyperuricaemia and its clinical
manifestations in patients with refractory chronic gout and no
other urate-lowering options. In the present OLE of two
RCTs,17 long-term treatment with pegloticase was safe and
generally well tolerated, especially in patients who had experi-
enced sustained goal range urate-lowering responses during
blinded treatment. In addition to maintaining markedly sub-
saturating urate levels, these patients showed progressive clin-
ical beneﬁt in gout ﬂares and tophus reduction during pegloti-
case treatment for an average of 2 years in the OLE study.
Figure 4 Proportions of patients who received (A) biweekly pegloticase or (B) monthly pegloticase throughout the randomised controlled trial (RCT)
and open-label extension periods and reported gout ﬂares (per 3-month interval).
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Target range SUA was achieved for 55% of all patients at
week 25 of the OLE study. This is consistent with ﬁndings
from the RCTs in which 42% of patients treated with biweekly
pegloticase showed sustained urate lowering for 6 months.17
Conversely, patients losing urate-lowering efﬁcacy did so
within the ﬁrst few months of treatment in the RCTs, and
urate levels for this cohort remained above target for the dur-
ation of the OLE study. About one-third of patients who did
not sustain SUA<6 mg/dl in the RCTs retained clinical beneﬁt
during the OLE study with at least one tophus remaining
resolved. However, this ﬁnding could be explained by an
initial response followed by a protracted period needed for sufﬁ-
cient reaccumulation of crystal deposits to become clinically
detectable.
A post hoc analysis of the RCTs revealed relationships
between loss of urate-lowering efﬁcacy, risk of IRs and develop-
ment of high-titre pegloticase antibodies.17 Because of blinding
of urate levels during the RCTs, the relationship between loss
of urate-lowering efﬁcacy and the risk of pegloticase infusion
reactions was not appreciated until several months after initi-
ation of the OLE study. As a result, some patients who were
RCT pegloticase non-responders continued receiving pegloti-
case during the OLE study, providing additional information
with regard to these relationships. Among patients entering the
OLE study, 71 had at least one IR during the randomised trials
or the OLE study; 85% of these patients (60/71) experienced
their ﬁrst IR when SUA was >6 mg/dl. Overall, these data
support the view that the great majority of IRs can be avoided
if patients discontinue treatment when, with routine preinfu-
sion monitoring of SUA, levels in excess of 6 mg/dl indicate a
sustained loss of pegloticase urate-lowering efﬁcacy.
There are limitations to this study. First, the open-label
study design carries both well-documented value and some bias
as a result of being uncontrolled.19 Second, the RCT protocol
called for stratiﬁcation of patients based on treatment response
and dosing schedule. Although this provided the opportunity
to follow safety and efﬁcacy outcomes during the OLE study
for patients with speciﬁc treatment histories, it also resulted in
six distinct cohorts, each containing small numbers of patients.
Nevertheless, the analyses of OLE study data indicate that
patients who achieve treatment success throughout the ﬁrst
6 months of treatment are likely to beneﬁt from sustained long-
term urate-lowering by pegloticase with favourable clinical
responses. Conversely, patients not sustaining urate-lowering
treatment responses to pegloticase infusions should not be
expected to have treatment beneﬁts (extending substantially
beyond the period of urate-lowering initially achieved) and
incur an increased risk of IRs. We recommend discontinuation
of pegloticase therapy in such patients.
A ﬁnal limitation is that patients were identiﬁed by their
initial allocation to biweekly or monthly treatment in the
RCTs but were allowed to change dosing frequency at two
time points upon entering the OLE study. A higher proportion
of patients switched from monthly to biweekly treatment than
vice versa, however, indicating that most patients were receiv-
ing the US FDA-approved pegloticase biweekly regimen.
In summary, the safety proﬁle of pegloticase in the OLE
study was consistent with that observed in the RCTs17 with
no evidence of new safety concerns related to long-term expos-
ure. Efﬁcacy ﬁndings further demonstrated that clinical
improvements were durable and probably progressive during
long-term therapy in patients with persistent goal range urate-
lowering responses to pegloticase.
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